These are the highlights at ASCO 2021
This year's programme again includes advances in screening, treatment and also prevention of a wide range of tumor entities.
The motto: "Justice: Every patient. Every day. Everywhere."
A total of around 4,900 abstracts have been registered for ASCO 2021. We would like to share some of these with you today as highlights of the upcoming congress. This year's programme again includes advances in screening, treatment and also prevention of a wide range of tumor entities.
The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting will take place online from 4 to 8 June. Once again, ASCO will bring together thousands of experts from around the world to discuss the latest research findings from all areas of oncology over the four days of the conference.
The theme of this year's ASCO 2021 is also "Justice: Every Patient. Every day. Everywhere." The discussions during the meeting are primarily intended to help find new ways to give as many patients as possible access to the latest advances in cancer medicine, allowing them to benefit from the highest quality cancer therapies.
Nearly 5,000 individual papers in the programme
More than 2,450 abstracts will be presented at this year's virtual ASCO and another 2,450 abstracts will be published online. Most of the abstracts will be available for public viewing in the ASCO Meeting Library from Wednesday 19 May at 17:00.
Among them are the following highlights:
- Results of a study assessing the association between Medicaid income limits and long-term survival after cancer diagnosis in the US (abstract 6512).
- Results of a study that examined the association between increased screening for prostate specific antigen (PSA) and prostate cancer diagnoses in younger African American patients (Abstract 5004).
- A study examining the impact of screening and vaccination on HPV-related cancers in the US over the past 15 years (abstract 107).
- Results from the global phase III IMpower010 study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected non-small cell lung cancer (abstract 8500).
- Results from the phase III RELATIVITY-047 trial, which investigated combination treatment with two immunotherapies (relatlimab plus nivolumab) compared to nivolumab in the first-line treatment of patients with advanced melanoma (abstract 9503).
From 3 June, further highlight studies will follow, such as:
- Results of the randomised, placebo-controlled phase III OlympiA trial investigating the use of adjuvant olaparib after (neo-)adjuvant chemotherapy in patients with germline BRCA1 and BRCA2 mutations and HER2-negative high-risk primary breast cancer (abstract LBA1, plenary).
- Results from the phase III VISION trial investigating the use of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (abstract LBA4, plenary).
- Results from the randomised, double-blind phase III study KEYNOTE-564 evaluating the postoperative use of pembrolizumab compared to placebo in patients with renal cell carcinoma (abstract LBA5, plenary).
esanum will report on ASCO 2021 in June with articles, video interviews and podcast episodes and will keep an eye on these highlights for you. So come back to us from 4 June 2021 and stay up-to-date with the congress coverage of ASCO 2021 on esanum.de.